The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects
about
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachOverview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects.The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population.Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.Cardiovascular effects of fingolimod: A review article.Fingolimod for relapsing multiple sclerosis: an update.Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.Bitopic Sphingosine 1-Phosphate Receptor 3 (S1P3) Antagonist Rescue from Complete Heart Block: Pharmacological and Genetic Evidence for Direct S1P3 Regulation of Mouse Cardiac Conduction.Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod.Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.Clinical pharmacokinetics of fingolimod.Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.Prolonged and symptomatic bradycardia following a single dose of fingolimod.Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
P2860
Q22305854-643C496B-F403-4A39-9B64-DB1A727DA359Q30458371-2BEA75A6-27B9-49B8-A316-84E714ECBA8DQ30838717-742CEBA3-BBC0-4D2F-AD52-332DA4107A42Q33633042-B8E35691-9921-4802-AAFB-4CE9714D7B6FQ33756452-506656F3-2CAE-4A4E-BB7B-2B1B787BA5F9Q34396876-F61050E1-B0AE-48DA-9A5E-620B6B255EAAQ34558943-A09419D4-8AF8-4045-91DE-648157F529E1Q34618474-CA9208FB-E904-4C57-BE75-489AE6BE89F8Q35683275-B0D3FB14-17EC-49B6-B359-B54EE3C8C51EQ35953902-032DA88B-5F87-4804-BD01-1FD9CAF2F896Q36432399-02EB2614-EEB1-4180-92D2-AB95E50498C2Q36664563-5F7AC2D9-F2CD-45DD-9569-73B2913F838FQ37930972-7C99A96C-12C0-4A33-B155-530E20B6C88AQ37965580-2BDF7A10-B849-4577-9D2E-DD5848817845Q42601315-A235C58B-1288-4E64-8300-4E3951B8D19AQ44662050-3CD45068-3CA2-4028-80EA-670C4FFE3566Q44879438-C5F09556-90BC-4B1E-B683-B2805C2EAEECQ46178229-DDD7F9FC-7A93-4927-A6ED-EC0AC41BC4A3
P2860
The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The ability of atropine to pre ...... fingolimod in healthy subjects
@ast
The ability of atropine to pre ...... fingolimod in healthy subjects
@en
type
label
The ability of atropine to pre ...... fingolimod in healthy subjects
@ast
The ability of atropine to pre ...... fingolimod in healthy subjects
@en
prefLabel
The ability of atropine to pre ...... fingolimod in healthy subjects
@ast
The ability of atropine to pre ...... fingolimod in healthy subjects
@en
P2093
P2860
P1476
The ability of atropine to pre ...... fingolimod in healthy subjects
@en
P2093
Alan Slade
Daniel Neddermann
Gilles-Jacques Riviere
John M Kovarik
Robert L Schmouder
Steve Maton
Thomas L Hunt
P2860
P304
P356
10.1111/J.1365-2125.2008.03199.X
P407
P577
2008-04-11T00:00:00Z